Core Viewpoint - Fresenius Medical Care (FMS) is set to report its first-quarter 2025 results, with expectations of revenue growth and improved earnings per share compared to the previous year [1][9]. Performance Drivers - The FME25 transformation program has delivered EUR 567 million in cumulative savings, aiding in operational efficiencies across various functions [2][12]. - Positive momentum in U.S. same-market treatment growth was noted, with a 0.5% increase in the fourth quarter of 2024, indicating successful clinic operations [3][6]. Segment Analysis - The Care Enablement segment experienced a 10% organic revenue increase and a six-fold rise in operating income, reaching a margin of 7.8% [4][7]. - The Care Delivery segment showed stabilization with slight growth in treatment volumes, although it continues to face challenges from elevated mortality rates and labor shortages [6][5]. Financial Estimates - The Zacks Consensus Estimate for revenues is $5.25 billion, reflecting a 2.3% year-over-year growth, while earnings per share are estimated at $0.43, indicating a 19.4% improvement [9][10]. Long-Term Growth Potential - FMS aims for EUR 750 million in sustainable cost savings by the end of 2025, an increase from the previous target, with significant operational improvements already achieved [12]. - The upcoming launch of the FDA-approved 5008X Hemodiafiltration system is expected to enhance patient outcomes and drive growth [13]. Value-Based Care Strategy - The company is expanding its value-based care model through InterWell Health, managing over $11 billion in medical costs, with expectations of breakeven performance in 2025 [14].

One stock that might be an intriguing choice for investors right now is Fresenius Medical Care AG (FMS) . This is because this security in the Medical - Instruments space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in ...

Core Viewpoint - The stock market is experiencing volatility due to U.S. tariffs and global trade tensions, with the S&P 500 down over 8% for the year [1] Group 1: Market Conditions - U.S. tariffs on imports from major partners like China have reached as high as 145%, while China has imposed 84% duties on U.S. products [1] - Ongoing inflation pressures and concerns about a potential recession or stagflation are contributing to market uncertainty [1] Group 2: Investment Strategy - Investors are encouraged to focus on relative price strength, identifying stocks that outperform their peers even in volatile conditions [2] - Stocks that have shown better performance than the S&P 500 over the last 1 to 3 months, combined with solid fundamentals, indicate potential for growth [6] Group 3: Recommended Stocks - IHS Holding Limited (IHS) is highlighted for its strong growth potential, with a Zacks Consensus Estimate indicating 114.7% growth for 2025 earnings and a market cap of $1.6 billion [10][11] - Atlanticus Holdings Corporation (ATLC) is noted for a 29.4% growth estimate for 2025 earnings and a significant share price increase of 110.5% over the past year [12][13] - REX American Resources Corporation (REX) has a market cap of $676.4 million and a 15.7% upward revision in earnings estimates for fiscal 2026, despite a 31.3% decline in share price over the past year [14][15] - Fresenius Medical Care AG (FMS) is recognized for a 27.1% growth estimate for 2025 earnings and a share price increase of 31.8% in the last year [16][17] Group 4: Screening Parameters - Stocks are screened based on relative price changes over 12 weeks, 4 weeks, and 1 week, as well as positive current-quarter estimate revisions [8] - Only Zacks Rank 1 (Strong Buy) stocks are considered, which have historically outperformed the S&P 500 [9]

Market Overview - President Trump's announcement of reciprocal tariffs led to significant volatility in the U.S. stock market, with the S&P 500 dropping 9% in the first week of April, its worst week since 2020, followed by a rebound of 5.7% the next week, marking the best week since 2023 [1] - Exemptions from tariffs on items such as smartphones, semiconductors, and solar cells contributed to a strong tech rally, although the S&P 500 remained below its level from April 2 [2] - Ongoing uncertainty regarding a potential global trade war continues to concern investors and economists [2] Value Investing Strategy - Value investing focuses on purchasing stocks priced below their intrinsic value, capitalizing on market mispricing [4] - Earnings yield, calculated as (Annual Earnings per Share/Market Price) x 100, serves as a key metric for value investors, indicating potential undervaluation when high [5] - Earnings yield can be compared to bond returns, such as the 10-year Treasury yield, to assess the attractiveness of stocks relative to fixed-income securities [6] Stock Screening Criteria - A primary screening criterion is an Earnings Yield greater than 10%, supplemented by additional parameters such as estimated EPS growth for the next 12 months being greater than or equal to the S&P 500 [7] - Average Daily Volume (20 Day) should be greater than or equal to 100,000 to ensure adequate liquidity [8] - Current Price must be greater than or equal to $5, and stocks with a Zacks Rank 1 (Strong Buy) or 2 (Buy) are expected to outperform peers [9] Selected Stocks - **Alibaba Group (BABA)**: Dominates the e-commerce sector in China and is expanding internationally, with a Zacks Rank 1 and a Value Score of B. The consensus estimate for fiscal 2025 and 2026 earnings indicates year-over-year growth of 2.1% and 23% respectively [10][11] - **Fresenius Medical Care AG (FMS)**: A leading provider of dialysis products and services, recently launched a new home dialysis machine. The consensus estimate for 2025 and 2026 earnings suggests growth of 27.1% and 9.1% respectively [12][13] - **Helix Energy Solutions Group Inc. (HLX)**: Focuses on offshore energy services, with a consensus estimate for 2025 and 2026 earnings indicating growth of 42% and 28.2% respectively [14][15] - **Heritage Insurance Holdings, Inc. (HRTG)**: Provides residential insurance products with a focus on selective underwriting. The consensus estimate for 2025 and 2026 earnings suggests growth of 21% and 28.6% respectively [16][17]

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Concentra Group (CON) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Concentra Group is one of 1003 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and ...

Industry Overview - The MedTech sector has emerged as a resilient investment option amid macroeconomic challenges, characterized by innovation and a rising demand for personalized healthcare solutions [6][8] - The global MedTech industry market is projected to grow to $694.70 billion by 2025, with an estimated year-over-year increase of approximately 4% [8] Market Dynamics - The medical device industry has historically been a reliable refuge during turbulent market periods, with investors currently prioritizing long-term stability over short-term gains [4] - Innovations in artificial intelligence, robotics, and minimally invasive techniques are expected to revolutionize healthcare services, increasing the demand for advanced medical equipment and diagnostic instruments [8] Company Highlights - **Fresenius Medical Care AG (FMS)**: A leading provider of products and services for dialysis patients, recently launched the NxStage Versi HD home dialysis machine, with over 14,000 U.S. patients using its system [10][11] - FMS has a Zacks Rank of 1 and a Value Score of A, with a P/E ratio of 11.36X, below the industry average of 23.48X, and is expected to see a 27.1% growth in earnings by 2025 [12] - **Phibro Animal Health (PAHC)**: A global diversified animal health company that recently acquired Zoetis Inc.'s product portfolio, enhancing its profitability and EBITDA margin [14][15] - PAHC holds a Zacks Rank of 1 and a Value Score of B, with a P/E of 9.88X, below the industry average of 15.56X, and is projected to achieve 63% growth in earnings by 2025 [16] - **Cencora, Inc. (COR)**: A major pharmaceutical services company that launched Accelerate Pharmacy Solutions and is expanding its leadership in specialty products through strategic acquisitions [17][18] - COR has a Zacks Rank of 2 and a Value Score of B, with a P/S ratio of 0.18X, significantly lower than the industry average of 1.29X, and is expected to see an 11.6% growth in earnings by 2025 [19]

Core Viewpoint - Fresenius Medical Care AG & Co. (FMS) is positioned for growth through strategic acquisitions and partnerships, despite facing a challenging regulatory environment [1][8]. Company Overview - FMS has a market capitalization of $15.06 billion and is a leading provider of dialysis products and services for chronic kidney failure patients [2]. - The company's earnings are expected to improve by 11.9% over the next five years, with a history of beating earnings estimates in the last four quarters, averaging a surprise of 15.67% [2]. Growth Factors - **Strategic Acquisitions & Partnerships**: FMS has acquired NxStage Medical for $30 per share, anticipating earnings accretion within three years and annual pre-tax savings of $80 million to $100 million. The 2025 growth strategy includes merging Fresenius Health Partners, InterWell Health, and Cricket Health to manage 270,000 kidney disease patients with $11 billion in medical costs. Additionally, FMS has expanded its home dialysis market through a distribution deal with JMS Co. Ltd. in Japan and extended agreements with DaVita and Aetna [3]. - **Strong Global Foothold**: FMS has a robust presence in North America, Europe, Asia Pacific, and Latin America, achieving organic growth and strategic acquisitions. The company entered the dialysis market in Israel and acquired an 85% stake in Sandor Nephro Services in India, while also focusing on public-private partnerships to explore new markets [4]. - **Strong Q4 Results**: FMS reported strong Q4 results, surpassing earnings and revenue estimates, driven by pricing momentum in the Care Enablement segment [5]. Financial Performance - The FME25 transformation program achieved EUR 221 million in sustainable savings in 2024, exceeding its target, with total accumulated savings reaching EUR 567 million. FMS has raised its 2025 savings target to EUR 750 million, despite expected one-time costs of EUR 700-750 million [7]. - The Zacks Consensus Estimate for 2025 revenues is $21.08 billion, indicating flat year-over-year growth, while the consensus for earnings is $2.11 per share, reflecting a growth of 27.1% from the previous year. Earnings estimates have improved by 19 cents in the past 90 days [9].

The U.S. stock market experienced a strong rebound earlier this week, as the Dow Jones Industrial Average gained 500 points, and the S&P 500 and the Nasdaq Composite rose 1.5% and 1.8%, respectively, on March 24. This rally has, to some extent, rekindled investor interest in equities, which had been under pressure amid concerns about recession and policy-induced trade disruptions.The latest gains stem from renewed investor optimism following indications that President Trump's upcoming set of tariffs may be ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

In 2024, the operating model to deliver the highest quality of patient care was further optimized by enhancing financial returns, and creating value for shareholders Fresenius Medical Care delivered 18% operating income growth on an outlook base in 2024 Ongoing progress has been achieved in key areas of sustainability: notably in patient care and environmental footprintBAD HOMBURG, Germany, March 13, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services fo ...